German drug manufacturing company Boehringer Ingelheim GmbH has agreed to settle approximately 4,000 lawsuits for $650 million. The lawsuits were filed over blood thinning drug Pradaxa, which has been linked to more than 540 patient deaths.
Boehringer is seeking to settle these lawsuits before the first U.S. trial on the matter begins in September. The settlement would provide an average per-case payout of approximately $162,500.
In Illinois, 2,500 lawsuits have been consolidated while another 1,500 are in state courts throughout Connecticut, California and Delaware.
According to Bloomberg, patients and their families allege that Boehringer executives knew the drug posed a deadly risk when it was introduced in to the market in October 2010. Last year, researchers came up with an experimental antidote for Pradaxa which has generated more than $1 billion in sales worldwide for the drug manufacturer.
Earlier this month, Boehringer announced that they had complete a new analysis of a company-funded study that was used to win approval of Pradaxa. The analysis revealed that 22 serious bleeding events were not included in the original report.
By 2011, the FDA had received more than 540 reports of death linked to the drug and an additional 3,780 reports of serious side-effects.
Additionally, in 2012 Boehringer issued a voluntary recall of a single manufacturing lot of Pradaxa. The recall was issued due to a potential packaging defect that could allow moisture to get into the bottle and impair the quality of the drug. If a patient does not receive a fully effective dose of the drug, they are at increased risk of experiencing an ischemic stroke.
If you or a loved one has suffered from internal bleeding after taking Pradaxa, you are encouraged to contact a Pradaxa injury lawyer to explore your legal options. Contact The Eichholz Law Firm at (866) 947-7449 to get connected with one of our experienced attorneys.